CLINICAL TRIAL ENDPOINTS FOR OPTICAL COHERENCE TOMOGRAPHY ANGIOGRAPHY IN NEOVASCULAR AGE-RELATED MACULAR DEGENERATION

Retina. 2016 Dec:36 Suppl 1:S83-S92. doi: 10.1097/IAE.0000000000001338.

Abstract

Purpose: To describe qualitative and quantitative optical coherence tomography (OCT) angiography (OCTA) parameters for choroidal neovascularization (CNV) secondary to age-related macular degeneration (AMD) and their applicability as potential clinical trial endpoints.

Methods: A review of current literature related to the topic of OCTA and AMD.

Results: There are a number of promising OCTA parameters that can be used to diagnose the presence of CNV and to monitor the activity and progression of the lesion, pre- and post-treatment morphological characteristics, CNV dimensions, and automated quantitative parameters such as vessel density.

Conclusion: The OCTA parameters described in this review have promise for the future development of clinical trial endpoints, but require further validation before they can be widely used.

Publication types

  • Review

MeSH terms

  • Angiogenesis Inhibitors / therapeutic use
  • Choroidal Neovascularization / diagnostic imaging
  • Choroidal Neovascularization / drug therapy
  • Choroidal Neovascularization / etiology*
  • Clinical Trials as Topic
  • Humans
  • Macular Degeneration / complications*
  • Macular Degeneration / diagnostic imaging
  • Tomography, Optical Coherence / methods
  • Vascular Endothelial Growth Factor A / antagonists & inhibitors

Substances

  • Angiogenesis Inhibitors
  • Vascular Endothelial Growth Factor A